Literature DB >> 19896334

Social disability in schizophrenic, schizoaffective and affective disorders 15 years after first admission.

Ronald Bottlender1, Anton Strauss, Hans-Jürgen Möller.   

Abstract

BACKGROUND: Interest in social functioning of people suffering from mental illnesses has been increasing over the last few years. Only few studies have investigated differences in social functioning in affective, schizoaffective and schizophrenic patients in the long-term and in a comparative approach.
METHOD: The present study is part of a 15 year follow-up study on patients suffering from severe mental illness. The here reported findings refer to the data of a sample of 177 patients with life-time diagnoses belonging to the schizophrenic, schizoaffective or affective spectrum according to the ICD-10 criteria. Psychopathological, socio-demographic and other illness-related variables were assessed at the index hospitalisation and at the 15 year follow-up evaluation by using the assessment system published by the Association for Methodology and Documentation in Psychiatry (AMDP-system). Information about patients' social disability was assessed by using a modified and further developed version of the WHO disability assessment scale, the (Mannheim) Disability Assessment Schedule (DAS-M scale). Prevalence rates of social disability and differences in the severity of social disability between different groups of mental illnesses were evaluated. And the association between social disability, diagnoses and psychopathology was analysed.
RESULTS: Compared to affective and schizoaffective patients, schizophrenic patients showed significantly higher levels of social disability in almost all domains. Severe to very severe levels of disability were found in 64% of schizophrenic patients and only in 19% of schizoaffective patients and 5% of affective patients. However, on a descriptive level all three diagnostic groups presented with similar maxima and minima in their profiles of social disability. Multiple regression analyses revealed that the apathy syndrome had the highest impact on the presence of severe social disability with all other psychopathological syndromes, gender, age and diagnosis having no statistically significant influence.
CONCLUSION: Findings indicate that patients' disabilities in different diagnostic groups seem to be of a similar quality and nature despite differences in their severity. The impact of psychopathology on disability seems to be more important than the one of diagnosis per se.

Entities:  

Mesh:

Year:  2010        PMID: 19896334     DOI: 10.1016/j.schres.2009.10.008

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  23 in total

1.  Association between psychopathology and problems of psychosocial functioning in the long-term outcome of patients diagnosed with schizophrenic, schizoaffective and affective disorders.

Authors:  Ronald Bottlender; Anton Strauss; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06-22       Impact factor: 5.270

Review 2.  Schizoaffective disorder: a review of current research themes and pharmacological management.

Authors:  Joshua T Kantrowitz; Leslie Citrome
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

Review 3.  Information and decision-making needs among people with mental disorders: a systematic review of the literature.

Authors:  Lisa Tlach; Caroline Wüsten; Anne Daubmann; Sarah Liebherz; Martin Härter; Jörg Dirmaier
Journal:  Health Expect       Date:  2014-08-21       Impact factor: 3.377

Review 4.  Social cognition as a mediator variable between neurocognition and functional outcome in schizophrenia: empirical review and new results by structural equation modeling.

Authors:  Stefanie J Schmidt; Daniel R Mueller; Volker Roder
Journal:  Schizophr Bull       Date:  2011-09       Impact factor: 9.306

5.  Functional impairment among people with severe and enduring mental disorder in rural Ethiopia: a cross-sectional study.

Authors:  Kassahun Habtamu; Atalay Alem; Girmay Medhin; Abebaw Fekadu; Charlotte Hanlon
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2018-06-14       Impact factor: 4.328

6.  Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies.

Authors:  Ilja Spellmann; Rebecca Schennach; Florian Seemüller; Sebastian Meyer; Richard Musil; Markus Jäger; Max Schmauß; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Michael Bauer; Mazda Adli; Joachim Zeiler; Wolfram Bender; Klaus-Thomas Kronmüller; Marcus Ising; Peter Brieger; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Michael Riedel; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-10-26       Impact factor: 5.270

7.  The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity.

Authors:  Hans-Jürgen Möller; Markus Jäger; Michael Riedel; Michael Obermeier; Anton Strauss; Ronald Bottlender
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-05-22       Impact factor: 5.270

8.  Gender differences in outcomes in people with schizophrenia in rural China: 14-year follow-up study.

Authors:  Mao-Sheng Ran; Wen-Jun Mao; Cecilia Lai-Wan Chan; Eric Yu-Hai Chen; Yeates Conwell
Journal:  Br J Psychiatry       Date:  2015-01-08       Impact factor: 9.319

9.  Lack of Gender-Related Differences in Childhood-Onset Schizophrenia.

Authors:  Anna E Ordóñez; Frances F Loeb; Xueping Zhou; Lorie Shora; Rebecca A Berman; Diane D Broadnax; Peter Gochman; Siyuan Liu; Judith L Rapoport
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2016-07-01       Impact factor: 8.829

10.  Reduced safety processing during aversive social conditioning in psychosis and clinical risk.

Authors:  Megan Quarmley; Ruben C Gur; Bruce I Turetsky; Anna J Watters; Warren B Bilker; Mark A Elliott; Monica E Calkins; Christian G Kohler; Kosha Ruparel; Petra Rupert; Raquel E Gur; Daniel H Wolf
Journal:  Neuropsychopharmacology       Date:  2019-05-21       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.